The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 537-552

  Richardson, Frank ^a   Young, G David ^b   Sennello, Regina ^a   Wolf, Julie ^c   Argast, Gretchen M ^a   Mercado, Peter ^a   Davies, Angela ^a   Epstein, David M ^a   Wacker, Bret ^c  

^a OSI PHARMACEUTICALS INC   (United States)

^b Flagship Biosciences   (United States)

^c Novella Clinical   (United States)

Author keywords

E Cadherin; EMT; Erlotinib; Non small cell lung cancer; Vimentin

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOPLASM; FEMALE; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STAINING; TUMOR CELL;

ADOLESCENT; ADULT; AGED; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL; VIMENTIN; YOUNG ADULT;

EID: 84856927351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Grandis JR and Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102(1): 37-46, 2004. (Pubitemid 38429984)
2. Dancey JE: Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 5(5): 411-415, 2004.
3. Nagane M, Lin H, Cavenee WK and Huang HJ: Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162: S17-21, 2001
4. Fuster LM and Sandler AB: Select clinical trials of erlotinib (OSI-774) in non-small cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 6(Suppl 1): S24-29, 2004.
5. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
6. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
7. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
8. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, and Giaccone G: SATURN investigators: Erlotinib as maintenance treatment in advanced nonsmall cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529, 2010.
9. Shepherd FA and Tsao MS: Epidermal growth factor receptor biomarkers in non-small cell lung cancer, A riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 28: 903-905, 2010.
10. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P and Haley JD: Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6: 532-541, 2007. (Pubitemid 46332455)
11. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462, 2005. (Pubitemid 41508014)
12. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V and Amler LC: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698, 2005. (Pubitemid 43005918)
13. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD and Bunn PA Jr.: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950, 2006. (Pubitemid 43165962)
14. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr. and Raben D: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691, 2007. (Pubitemid 46954044)
15. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP and McConkey DJ: Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6: 277-285, 2007. (Pubitemid 46206692)
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P and Seymour L: National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
17. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005. (Pubitemid 41058345)
18. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA and Tsao MS: NCIC-CTG BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
19. Argast GM, Mercado P, Mulford IJ, O'Conner M, Keane DM, Shaaban S, Epstein DM, Pacther JA and Kan JL: Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs 193: 114-132, 2011.
20. Miyanaga A, Gemma A, Ando M, Kosaihira S, Noro R, Minegishi Y, Kataoka K, Nara M, Okano T, Miyazawa H, Tanaka T, Yoshimura A, Kobayashi K, Iwanami H, Hagiwara K, Tsuboi E and Kudoh S: E-Cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep 19: 377-383, 2008. (Pubitemid 351176097)
21. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R and Yokomise H: Clinical application of biological markers for treatments of resectable non-small cell lung cancers. Br J Cancer 92: 1231-1239, 2005. (Pubitemid 40604397)
22. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA: High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in nonsmall cell lung cancer. J Clin Oncol 20: 2417-2428, 2002. (Pubitemid 34525727)
23. Al-Saad S, Al-Shibli K, Donnern T, Persson M, Bremnes RM and Busund LT: The prognostic impact of NF-kappaß p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small cell lung cancer. Br J Cancer 99: 1476-1483, 2008.